AP209 / Aprogen - LARVOL DELTA

Aprogen announced on the 30th that, following its recent approval of the Investigational New Drug (IND) application for AP209 from the Ministry of Food and Drug Safety, it submitted the necessary documents to the Institutional Review Board (IRB) at Kyung Hee University Hospital on the 29th to initiate the clinical trial (eDaily) - "The submitted documents included the clinical trial protocol, patient consent forms, a list of trial sites and investigators, case report forms (CRFs), and the investigator’s brochure, thereby completing the paperwork required to begin the trial....This clinical trial is scheduled to be conducted at three to four university hospitals, including Kyung Hee University Hospital, with 16 patients with osteoarthritis."

New trial • Osteoarthritis